Published in J Virol on July 19, 2017
Programming the magnitude and persistence of antibody responses with innate immunity. Nature (2011) 5.18
Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med (2012) 4.74
Dating the emergence of pandemic influenza viruses. Proc Natl Acad Sci U S A (2009) 4.36
Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio (2010) 4.15
Epidemiology of seasonal influenza: use of surveillance data and statistical models to estimate the burden of disease. J Infect Dis (2006) 3.66
Influenza vaccine effectiveness in the community and the household. Clin Infect Dis (2013) 3.40
Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A (2010) 3.24
Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci U S A (2012) 2.96
Key roles of adjuvants in modern vaccines. Nat Med (2013) 2.62
Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine (2008) 2.56
The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Vaccine (2013) 2.25
Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol (2013) 2.09
A carboxy-terminal trimerization domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin substrates. PLoS One (2012) 1.81
Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol (2013) 1.69
Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach. J Virol (2008) 1.64
Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J Virol (2013) 1.49
H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice. J Virol (2013) 1.48
The evolving history of influenza viruses and influenza vaccines. Expert Rev Vaccines (2013) 1.40
Hemagglutinin Stalk-Reactive Antibodies Are Boosted following Sequential Infection with Seasonal and Pandemic H1N1 Influenza Virus in Mice. J Virol (2012) 1.40
Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin. Curr Top Microbiol Immunol (2015) 1.32
MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev Vaccines (2011) 1.25
Synthesis and immunological characterization of toll-like receptor 7 agonistic conjugates. Bioconjug Chem (2009) 1.20
Innate immunity and adjuvants. Philos Trans R Soc Lond B Biol Sci (2011) 1.16
Innate and adaptive immune responses to viral infection and vaccination. Curr Opin Virol (2011) 1.15
Adjuvant solution for pandemic influenza vaccine production. Proc Natl Acad Sci U S A (2012) 1.14
H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge. J Virol (2013) 1.14
T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. J Infect Dis (2012) 1.14
Correlates of protection to influenza virus, where do we go from here? Hum Vaccin Immunother (2013) 1.12
A Sendai virus-derived RNA agonist of RIG-I as a virus vaccine adjuvant. J Virol (2012) 1.12
Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7. Proc Natl Acad Sci U S A (2009) 1.10
Universal influenza virus vaccines: need for clinical trials. Nat Immunol (2014) 1.09
An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. Expert Rev Vaccines (2013) 1.08
Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies. PLoS One (2013) 1.06
Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants. J Autoimmun (2014) 1.06
Identification of substituted pyrimido[5,4-b]indoles as selective Toll-like receptor 4 ligands. J Med Chem (2013) 0.99
Alternative influenza vaccines made by insect cells. Trends Mol Med (2010) 0.95
Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood. Proc Natl Acad Sci U S A (2016) 0.93
Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses. J Virol (2015) 0.90
Synthesis and characterization of PEGylated toll like receptor 7 ligands. Bioconjug Chem (2011) 0.86
Memory CD4 T cells in influenza. Curr Top Microbiol Immunol (2015) 0.83
Predicting the outcome of infectious diseases: variability among inbred mice as a new and powerful tool for biomarker discovery. MBio (2012) 0.82
Matrix M(TM) adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4(+) T cell responses in man. Hum Vaccin Immunother (2014) 0.82
Adjuvanting an SIV vaccine with TLR ligands encapsulated in nanoparticles induces persistent antibody responses and enhanced protection in TRIM5α restrictive macaques. J Virol (2016) 0.81
Early Rise of Blood T Follicular Helper Cell Subsets and Baseline Immunity as Predictors of Persisting Late Functional Antibody Responses to Vaccination in Humans. PLoS One (2016) 0.79
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis (2016) 0.78
Protection against H5N1 Influenza Virus Induced by Matrix-M Adjuvanted Seasonal Virosomal Vaccine in Mice Requires Both Antibodies and T Cells. PLoS One (2015) 0.78
Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies. Hum Vaccin Immunother (2015) 0.76
Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review. Hum Vaccin Immunother (2015) 0.76
Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo. Nat Med (2014) 2.72
Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol (2013) 2.09
Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. J Virol (2014) 1.26
Divergent H7 immunogens offer protection from H7N9 virus challenge. J Virol (2014) 1.16
H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge. J Virol (2013) 1.14
Universal influenza virus vaccines: need for clinical trials. Nat Immunol (2014) 1.09
Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies. Antimicrob Agents Chemother (2015) 0.94
Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Induce Potent Phagocytosis of Immune Complexes by Neutrophils in an Fc-Dependent Manner. MBio (2016) 0.94
Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination. Nat Med (2016) 0.93
Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses. J Virol (2015) 0.90
Domestic pigs are susceptible to infection with influenza B viruses. J Virol (2015) 0.86
Newcastle Disease Virus-Vectored H7 and H5 Live Vaccines Protect Chickens from Challenge with H7N9 or H5N1 Avian Influenza Viruses. J Virol (2015) 0.85
Hemagglutinin Stalk- and Neuraminidase-Specific Monoclonal Antibodies Protect against Lethal H10N8 Influenza Virus Infection in Mice. J Virol (2015) 0.85
Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains. J Virol (2015) 0.84
Cryo-electron Microscopy Structures of Chimeric Hemagglutinin Displayed on a Universal Influenza Vaccine Candidate. MBio (2016) 0.81
A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine. J Virol (2014) 0.81
Influenza A Viruses Expressing Intra- or Intergroup Chimeric Hemagglutinins. J Virol (2016) 0.79
Progesterone-Based Contraceptives Reduce Adaptive Immune Responses and Protection against Sequential Influenza A Virus Infections. J Virol (2017) 0.75
Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins. Nat Immunol (2017) 0.75